Compare ZGM & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZGM | CING |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 26.4M |
| IPO Year | 2025 | 2021 |
| Metric | ZGM | CING |
|---|---|---|
| Price | $2.73 | $4.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 39.1K | ★ 119.5K |
| Earning Date | 01-06-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 401.52 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $3,620,780.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | ★ 211.78 | N/A |
| 52 Week Low | $1.90 | $3.20 |
| 52 Week High | $4.51 | $6.01 |
| Indicator | ZGM | CING |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 71.13 |
| Support Level | N/A | $3.75 |
| Resistance Level | N/A | $4.02 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 0.00 | 96.30 |
Zenta Group Co Ltd is engaged in the provision of industrial park consultation services, business investment consultation services to clients through LIC, and sales of fintech products and services through LFT. Its industrial park consultation services are focused on the pre-development stage. Its business investment consultation services, offered through LIC, mainly focus on assisting clients to acquire stakes in specific investments, and it's normally in the form of equity ownership.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.